Get the Stockscreener App
36.34
3.47%
1.22
Roivant Sciences Ltd stock is traded at $36.34, with a volume of 6.74M.
It is up +3.47% in the last 24 hours and up +0.08% over the past month.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
See More
Previous Close:
$35.12
Open:
$35.88
24h Volume:
6.74M
Relative Volume:
1.17
Market Cap:
$26.14B
Revenue:
$8.26M
Net Income/Loss:
$-397.91M
P/E Ratio:
-72.16
EPS:
-0.5036
Net Cash Flow:
$-758.56M
1W Performance:
+7.17%
1M Performance:
+0.08%
6M Performance:
+40.74%
1Y Performance:
+214.63%
1-Day Range:
$35.62
$36.44
1-Week Range:
$32.47
$36.44
52-Week Range:
$10.90
$37.00
Roivant Sciences Ltd Stock (ROIV) Company Profile
Name
Roivant Sciences Ltd
Sector
Industry
Phone
441-295-5950
Address
7TH FLOOR, 50 BROADWAY, LONDON
Compare ROIV vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
36.34 | 24.97B | 8.26M | -397.91M | -758.56M | -0.5036 |
VRTX
Vertex Pharmaceuticals Inc
|
496.07 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.36 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
865.04 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.15 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
348.27 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-20-26 | Initiated | Bernstein | Outperform |
| Sep-02-25 | Initiated | Citigroup | Buy |
| Jul-10-25 | Resumed | Goldman | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Jan-05-24 | Initiated | Piper Sandler | Overweight |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-17-23 | Initiated | Guggenheim | Buy |
| Jun-08-23 | Initiated | BofA Securities | Neutral |
| Oct-27-22 | Initiated | JP Morgan | Overweight |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-29-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-15-21 | Initiated | Goldman | Buy |
| Nov-08-21 | Initiated | H.C. Wainwright | Buy |
| Oct-28-21 | Initiated | Citigroup | Buy |
| Oct-26-21 | Initiated | Cowen | Outperform |
| Oct-26-21 | Initiated | Jefferies | Buy |
| Oct-26-21 | Initiated | Truist | Buy |
View All
Roivant Sciences Ltd Stock (ROIV) Latest News
Roivant Sciences Ltd (ROIV) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Roivant Sciences (ROIV) affiliate files to sell 200,000 common shares after option exercise - Stock Titan
Roivant Sciences Ltd. Revenue Breakdown – SWB:87S - TradingView
Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026 - marketscreener.com
Roivant Sciences Ltd (ROIV) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Roivant Sciences Ltd (ROIV) Income Statement - TradingKey
ROIV|Roivant Sciences Ltd|Price:34.710|Chg%:-0.300 - TradingKey
TradingKey - TradingKey
Roivant Sciences Ltd (ROIV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Roivant Sciences Ltd. Revenue Breakdown – TRADEGATE:87S - TradingView
ROIV|Roivant Sciences Ltd|Price:35.010|Chg%:-0.090 - TradingKey
Dimensional Fund Advisors LP Sells 1,771,602 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences Ltd. (ROIV) Stock Price, News, Quote & History - Yahoo! Finance Canada
Bank of Nova Scotia Cuts Stake in Roivant Sciences Ltd. $ROIV - MarketBeat
Allspring Global Investments Holdings LLC Buys New Stake in Roivant Sciences Ltd. $ROIV - MarketBeat
ROIV Stock Nears Record High –Retail Traders See Breakout After Surprise Earnings Beat - Stocktwits
Roivant Sciences Ltd. (ROIV) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Roivant Sciences (ROIV) Edges Lower as Stock Consolidates Near Support ZoneInsider Sentiment - dars.gov.et
Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
California Public Employees Retirement System Invests $19.15 Million in Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences Ltd. (ROIV) stock price, news, quote and history - Yahoo Finance UK
Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026 - marketscreener.com
Baader Bank Aktiengesellschaft Sells 33,612 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant to report Q1 results, host conference call and webcast - Bitget
Immunovant (NASDAQ: IMVT) plans 2026 votes on directors, auditor and pay - Stock Titan
Roivant Sciences Holds Steady Near $35 Amid Measured TradingAI Trade Signals - dars.gov.et
Roivant Sciences Ltd. (ROIV) Stock forecasts - Yahoo Finance UK
Bank of New York Mellon Corp Decreases Stock Holdings in Roivant Sciences Ltd. $ROIV - MarketBeat
Form 4 Roivant Sciences Ltd. For: 21 July By Investing.com - Investing.com Nigeria
Form 4 Roivant Sciences Ltd. For: 21 July - Investing.com India
Roivant Sciences (ROIV) grants director Oren Ilan 775 fully vested shares - Stock Titan
Responsive Playbooks and the ROIV Inflection - Stock Traders Daily
Illinois Municipal Retirement Fund Boosts Stake in Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences Ltd. (ROIV) Stock Analysis: Exploring a 13.93% Upside in Biotech Innovation - DirectorsTalk Interviews
Why is Billionaire Joe Edelman Bullish on Roivant Sciences (ROIV) - Kavout | AI
Pfizer, BioNTech face global patent suits from Arbutus, Roivant over COVID vaccine tech - Seeking Alpha
Roivant Sciences Ltd. (ROIV) Stock Analysis: Exploring the 9.47% Upside Potential in Biotech Innovation - DirectorsTalk Interviews
Roivant Sciences (ROIV) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Candriam S.C.A. Lowers Position in Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant’s Gline: From spin-cos to commercial conviction - BioCentury
Roivant Sciences (ROIV) Climbs 2%: Biotech Stock Tests Key Resistance Near $38.65Moving Average Ribbon - dars.gov.et
Roivant Sciences (ROIV) TD Cowen 45th Annual Healthcare Conference Summary - Quartr
Roivant Sciences stock hits all-time high at 35.92 USD By Investing.com - Investing.com Nigeria
Roivant Sciences stock hits all-time high at 35.92 USD - Investing.com
Could Roivant Sciences Be a Multibagger Stock Over the Next 5 Years? - Yahoo Finance
Roivant Sciences Ltd. (ROIV) Stock Analysis: Potential Upside Amidst Biotech Innovations - DirectorsTalk Interviews
If You Invested $1,000 in Roivant Sciences (ROIV) - Stock Titan
ROIVRoivant Sciences Ltd Dividends - Finviz
Roivant Sciences Insider Sold Shares Worth $610,252, According to a Recent SEC Filing - Moomoo
Roivant Sciences (ROIV) director exercises options, sells 10,000 common shares - Stock Titan
Roivant Sciences (ROIV) Edges Lower, Consolidating Between Key Support and Resistance LevelsRegression Channel - dars.gov.et
Roivant Sciences Ltd Stock (ROIV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Roivant Sciences Ltd Stock (ROIV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Venker Eric | President & Immunovant CEO |
Jul 27 '26 |
Sale |
34.95 |
200,000 |
6,990,000 |
1,613,063 |
0.86%
1.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):